C-reactive protein anti cardiac allograft vasculopathy: Is inflammation the critical link?

Journal of the American College of Cardiology

Volumn 42, Issue 3, 2003, Pages 483-485

  Ventura, Hector O ^a   Mehra, Mandeep R ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CYCLOSPORIN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; LEUKOCYTE ANTIGEN; LIPID; PRAVASTATIN; PROCOAGULANT; SIMVASTATIN; STATIN;

ATHEROMA; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; ENDOTHELIUM CELL; GRAFT FAILURE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTRAVASCULAR ULTRASOUND; LIPID STORAGE; LIVER CELL; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION INJURY; SURGICAL MORTALITY; VASCULAR DISEASE;

EID: 0042628169     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00646-6     Document Type: Editorial

References (32)

1. Jacques J. Hippocrates. Baltimore, MD: John Hopkins University Press, 1999.
2. Shah PK. Circulating markers of inflammation for vascular risk prediction: are they ready for prime time. Circulation 2000;101:1758-9.
3. Ventura HO. Rudolph Virchow and cellular pathology. Clin Cardiol 2000;23:550-2.
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
5. Hognestad A, Endresen K, Wergeland R, et al. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol 2003;42:477-82.
6. Pethig K, Heublein B, Kutschka, Haverich A. Systemic inflammatory response in cardiac allograft vasculopathy: high sensitivity C-reactive protein is associated with progressive luminal obstruction. Circulation 2000;102 Suppl III:III233-6.
7. Eisenberg MS, Chen HJ, Warshofsky MK, et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 2000;102:2100-4.
8. Labarrere C, Lee JB, Nelson DR, et al. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 2002;360:1462-7.
9. Ventura HO, Mehra MR, Smart FW, Stapleton DD. Cardiac allograft vasculopathy: current concepts. Am Heart J 1995;129:791-9.
10. Mehra MR, Ventura HO, Chambers RB, et al. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 1995;26:1537-44.
11. Mehra MR, Ventura HO, Smart FW, Stapleton DD. The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: a paradigm shift. J Heart Lung Transplant 1995;14:207-11.
12. Mehra MR. Crossing the vasculopathy bridge from morphology to therapy: a single center experience. J Heart Lung Transplant 2000;196:522-8.
13. Rider AK, Copeland JG, Hunt SA, et al. The status of cardiac transplantation, 1975. Circulation 1975;52:531-9.
14. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med 1995;333:1111-6.
15. Valantine H, Rickenbacker P, Kemna M, et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 2001;103:2144-52.
16. Cantin B, Wen P, Zhu D, et al. Transplant coronary artery disease: a novel model independent of cellular alloimmune response. Circulation 2001;104:2615-9.
17. Labarrere CA, Nelson DR, Pitts DE, Kirlin PC, Halbrook H. Immunohistochemical model to predict risk for coronary artery disease and failure in heart transplant patients. Am J Transplant 2001;1:251-9.
18. Fyfe AI, Rothenburg LS, DeBeer FC, et al. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 1997;96:2914-9.
19. Gabay C, Kushner I. Acute phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
20. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
21. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events in apparently healthy women. Circulation 1998;98:731-3.
22. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6.
23. Rebuzzi AG, Quaranta G, Liuzzo G, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 1998;82:715-9.
24. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predicts recurrent instability. Circulation 1999;99:855-60.
25. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and risk of coronary, events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.
26. Mehra MR, Uber PA, Scott RL, Park MH, Milani RV. Effect of immunosuppressive regimen on novel markers of atherothrombosis in heart transplantation: homocysteine, C-reactive protein and mean platelet volume. Transplant Proc 2002;34:1866-8.
27. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
28. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.
29. Kobashigawa JA, Katznelson S, Laks H, et al. Effects of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
30. Mehra MR, Uber PA, Vivekananthan K, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002;40:609-14.
31. Albert MA, Danielson E, Rifai N, for the PRINCE investigators. Effect of statin therapy on C-reactive protein levels. JAMA 2001;286:64-70.
32. Katznelson S, Wang XM, Chia D, et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 1998;17:335-40.